Renal cell carcinoma (RCC) is the most lethal of all genitourinary tumors which standard and often curative treatment is based on radical nephrectomy or nephron sparing surgery. Since 2009 the treatment of metastatic and advanced RCC, following the cytoreductive surgery, has targeted antiangiogenic therapy combined with immunotherapy. The objective response rate to anti-angiogenic agents targeting VEGF, PDGF and thyrosine kinase inhibition like bevacizumab, sunitynib, sorafenib and others is almost twice higher than in previously used interferon and /or interleukin 2 immunotherapy. Future possibilities in stabilization of kidney cancer were discussed.